Shanghai Pharmaceuticals (02607) said its net profit attributable to equity holders for the first nine months of 2016 rose 12.78% year-on-year to Rmb2,457 million.
Basic and diluted earnings per share were Rmb91.38 cents.
Operating revenue amounted to Rmb90,517 million, an increase of 14.52% from a year earlier.
For the third quarter of 2016, Shanghai Pharmaceuticals' net profit attributable to equity holders grew 12.39% year-on-year to Rmb725 million.
etnet榮獲HKEX Awards 2023 「最佳表現證券數據供應商」大獎► 了解詳情
